Skip to content

Trial · Interventional

CompletedPhase 2Results postedRegistry data

Oxytocin and Affect Processing in Posttraumatic Stress Disorder

Overview

Status
Completed
Phase
Phase 2
Enrollment
11 participants (actual)
Sponsor
Yale University · Other
Design
Randomized · Double masking
Countries
1 country

United States

Start
Aug 2015
Primary completion
Aug 2016
Completion
Aug 2016
First posted
11 Sept 2015 (estimated)
Last update posted
8 Apr 2020
Conditions
Posttraumatic Stress Disorder (PTSD)

Timeline

1 trial · 1 completed · 1 with posted results

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
201520162017
  1. Ph 2

    Oxytocin and Affect Processing in Posttraumatic Stress Disorder

    NCT02546570

    Aug 2015 to Aug 2016

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

The investigators will use multiple methods (including Oxytocin intranasal inhalation, neuroimaging, behavioral measures, peripheral hormone measurements) to examine how individuals' behavior, cognition, and brain function is impacted by the neuro-hormone Oxytocin. Specifically, the investigators plan to evaluate the influence of Oxytocin administration on affective processing in non-trauma exposed and trauma-exposed adults (both with and without posttraumatic stress disorder, PTSD).

Interventions

  • OxytocinDrug
  • PlaceboDrug

Arms3

  • Experimental

    Healthy adult controls (18-55)

    Drug: oxytocin and placebo nasal spray (within-subjects design, blinded and counterbalanced for two lab sessions); dosage=24 international units (IU). Participant inserts nasal spray container 1cm into nostril at angle of 45 degrees and sprays. Will wait 15 seconds then repeat administration to other nostril (alternating between nostrils). Participants will receive 6 puffs in total (3 in each nostril).

  • Experimental

    Adults with PTSD (18-55)

    Drug: oxytocin and placebo nasal spray (within-subjects design, blinded and counterbalanced for two lab sessions); dosage=24 international units (IU). Participant inserts nasal spray container 1cm into nostril at angle of 45 degrees and sprays. Will wait 15 seconds then repeat administration to other nostril (alternating between nostrils). Participants will receive 6 puffs in total (3 in each nostril).

  • Experimental

    Trauma-exposed/no-PTSD adults (18-55)

    Drug: oxytocin and placebo nasal spray (within-subjects design, blinded and counterbalanced for two lab sessions); dosage=24 international units (IU). Participant inserts nasal spray container 1cm into nostril at angle of 45 degrees and sprays. Will wait 15 seconds then repeat administration to other nostril (alternating between nostrils). Participants will receive 6 puffs in total (3 in each nostril).

Primary outcomes7

Outcomes the sponsor listed as primary.

  1. fMRI Analysis: Change in Anterior Insula Region

    Time frame · 1 week; fMRI data collected at second and third visits, one week apart

    Registry description

    Change in blood-oxygen-level dependent (BOLD) contrast signal in regions of interest relevant to fear/threat (e.g., decrease in amygdala activation) and reward processing (increase in ventral striatum activation) in oxytocin versus placebo sessions. Forearm brush stroking targets C-tactile (CT) nerves, which respond to gentle touch and engage the insula and cortical brain regions that mediate social-emotional processing. Palm brush stroking is the control condition, in that CT afferents do not innervate the palm. We contrasted BOLD responses to gentle continuous brushing of the arm vs. palm (4 blocks of 8 trials each), expecting greater oxytocin-related increases in brain reactivity within the insula and other regions in the forearm condition versus the palm condition. The values are % signal change from baseline.

  2. fMRI Analysis: Change in Accumbens Region

    Time frame · 1 week; fMRI data collected at second and third visits, one week apart

    Registry description

    Change in blood-oxygen-level dependent (BOLD) contrast signal in regions of interest relevant to fear/threat (e.g., decrease in amygdala activation) and reward processing (increase in ventral striatum activation) in oxytocin versus placebo sessions. Forearm brush stroking targets C-tactile (CT) nerves, which respond to gentle touch and engage the insula and cortical brain regions that mediate social-emotional processing. Palm brush stroking is the control condition, in that CT afferents do not innervate the palm. We contrasted BOLD responses to gentle continuous brushing of the arm vs. palm (4 blocks of 8 trials each), expecting greater oxytocin-related increases in brain reactivity within the insula and other regions in the forearm condition versus the palm condition. The values are % signal change from baseline.

  3. fMRI Analysis: Change in Amygdala Region

    Time frame · 1 week; fMRI data collected at second and third visits, one week apart

    Registry description

    Change in blood-oxygen-level dependent (BOLD) contrast signal in regions of interest relevant to fear/threat (e.g., decrease in amygdala activation) and reward processing (increase in ventral striatum activation) in oxytocin versus placebo sessions. Forearm brush stroking targets C-tactile (CT) nerves, which respond to gentle touch and engage the insula and cortical brain regions that mediate social-emotional processing. Palm brush stroking is the control condition, in that CT afferents do not innervate the palm. We contrasted BOLD responses to gentle continuous brushing of the arm vs. palm (4 blocks of 8 trials each), expecting greater oxytocin-related increases in brain reactivity within the insula and other regions in the forearm condition versus the palm condition. The values are % signal change from baseline.

  4. fMRI Analysis: Change in dACC Region

    Time frame · 1 week; fMRI data collected at second and third visits, one week apart

    Registry description

    Change in blood-oxygen-level dependent (BOLD) contrast signal in regions of interest relevant to fear/threat (e.g., decrease in amygdala activation) and reward processing (increase in ventral striatum activation) in oxytocin versus placebo sessions. Forearm brush stroking targets C-tactile (CT) nerves, which respond to gentle touch and engage the insula and cortical brain regions that mediate social-emotional processing. Palm brush stroking is the control condition, in that CT afferents do not innervate the palm. We contrasted BOLD responses to gentle continuous brushing of the arm vs. palm (4 blocks of 8 trials each), expecting greater oxytocin-related increases in brain reactivity within the insula and other regions in the forearm condition versus the palm condition. The values are % signal change from baseline.

  5. fMRI Analysis: Change in mOFC Region

    Time frame · 1 week; fMRI data collected at second and third visits, one week apart

    Registry description

    Change in blood-oxygen-level dependent (BOLD) contrast signal in regions of interest relevant to fear/threat (e.g., decrease in amygdala activation) and reward processing (increase in ventral striatum activation) in oxytocin versus placebo sessions. Forearm brush stroking targets C-tactile (CT) nerves, which respond to gentle touch and engage the insula and cortical brain regions that mediate social-emotional processing. Palm brush stroking is the control condition, in that CT afferents do not innervate the palm. We contrasted BOLD responses to gentle continuous brushing of the arm vs. palm (4 blocks of 8 trials each), expecting greater oxytocin-related increases in brain reactivity within the insula and other regions in the forearm condition versus the palm condition. The values are % signal change from baseline.

  6. fMRI Analysis: Change in rACC Region

    Time frame · 1 week; fMRI data collected at second and third visits, one week apart

    Registry description

    Change in blood-oxygen-level dependent (BOLD) contrast signal in regions of interest relevant to fear/threat (e.g., decrease in amygdala activation) and reward processing (increase in ventral striatum activation) in oxytocin versus placebo sessions. Forearm brush stroking targets C-tactile (CT) nerves, which respond to gentle touch and engage the insula and cortical brain regions that mediate social-emotional processing. Palm brush stroking is the control condition, in that CT afferents do not innervate the palm. We contrasted BOLD responses to gentle continuous brushing of the arm vs. palm (4 blocks of 8 trials each), expecting greater oxytocin-related increases in brain reactivity within the insula and other regions in the forearm condition versus the palm condition. The values are % signal change from baseline.

  7. fMRI Analysis: Change in vmPFC Region

    Time frame · 1 week; fMRI data collected at second and third visits, one week apart

    Registry description

    Change in blood-oxygen-level dependent (BOLD) contrast signal in regions of interest relevant to fear/threat (e.g., decrease in amygdala activation) and reward processing (increase in ventral striatum activation) in oxytocin versus placebo sessions. Forearm brush stroking targets C-tactile (CT) nerves, which respond to gentle touch and engage the insula and cortical brain regions that mediate social-emotional processing. Palm brush stroking is the control condition, in that CT afferents do not innervate the palm. We contrasted BOLD responses to gentle continuous brushing of the arm vs. palm (4 blocks of 8 trials each), expecting greater oxytocin-related increases in brain reactivity within the insula and other regions in the forearm condition versus the palm condition. The values are % signal change from baseline.

Secondary outcomes(1)
  1. Salivary Oxytocin

    Time frame · Within session (30 min) and between sessions (1 week); saliva samples collected twice (before and after OT administration) at both second and third visits, one week apart

    Registry description

    Expect within-session (30 min) increase in peripheral salivary oxytocin level during OT sessions (within-session), and higher OT levels in oxytocin administration vs. placebo sessions. Peripheral OT levels measured with Salivettes (sterile cotton participants will be asked to chew on for 1 minutes).

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

Primary outcome results

Primary outcomeMean· 1 week; fMRI data collected at second and third visits, one week apart

fMRI Analysis: Change in Anterior Insula Region

GroupValue (percentage of area activation)
Adults With PTSD (18-55): Drug-12.6
Adults With PTSD (18-55): Placebo-1.6
Adults Without PTSD (18-55): Drug10.6
Adults Without PTSD (18-55): Placebo-7.8
Primary outcomeMean· 1 week; fMRI data collected at second and third visits, one week apart

fMRI Analysis: Change in Accumbens Region

GroupValue (percentage of area activation)
Adults With PTSD (18-55): Drug7.6
Adults With PTSD (18-55): Placebo-7.9
Adults Without PTSD (18-55): Drug-17.2
Adults Without PTSD (18-55): Placebo-12.7
Primary outcomeMean· 1 week; fMRI data collected at second and third visits, one week apart

fMRI Analysis: Change in Amygdala Region

GroupValue (percentage of area activation)
Adults With PTSD (18-55): Drug-3.8
Adults With PTSD (18-55): Placebo-9.1
Adults Without PTSD (18-55): Drug14.5
Adults Without PTSD (18-55): Placebo-6.7
Primary outcomeMean· 1 week; fMRI data collected at second and third visits, one week apart

fMRI Analysis: Change in dACC Region

GroupValue (percentage of area activation)
Adults With and Without PTSD (18-55): Drug-20.9
Adults With and Without PTSD (18-55): Placebo-16.4
Adults Without PTSD (18-55): Drug-4.8
Adults Without PTSD (18-55): Placebo-30.2
Primary outcomeMean· 1 week; fMRI data collected at second and third visits, one week apart

fMRI Analysis: Change in mOFC Region

GroupValue (percentage of area activation)
Adults With PTSD (18-55): Drug1.5
Adults With PTSD (18-55): Placebo2.5
Adults Without PTSD (18-55): Drug1.7
Adults Without PTSD (18-55): Placebo-8.1
Primary outcomeMean· 1 week; fMRI data collected at second and third visits, one week apart

fMRI Analysis: Change in rACC Region

GroupValue (percentage of area activation)
Adults With PTSD (18-55): Drug-5.9
Adults With PTSD (18-55): Placebo-4.4
Adults Without PTSD (18-55): Drug-0.2
Adults Without PTSD (18-55): Placebo-16.3
Primary outcomeMean· 1 week; fMRI data collected at second and third visits, one week apart

fMRI Analysis: Change in vmPFC Region

GroupValue (percentage of area activation)
Adults With and Without PTSD (18-55): Drug-3.8
Adults With and Without PTSD (18-55): Placebo-6.8
Adults Without PTSD (18-55): Drug-3.3
Adults Without PTSD (18-55): Placebo-16.0
Secondary and other outcome results(1)
Secondary outcome· Within session (30 min) and between sessions (1 week); saliva samples collected twice (before and after OT administration) at both second and third visits, one week apart

Salivary Oxytocin

GroupValue
Adults With PTSD (18-55): Drugnot posted
Adults With PTSD (18-55): Placebonot posted
Adults Without PTSD (18-55): Drugnot posted
Adults Without PTSD (18-55): Placebonot posted

Adverse events, as posted

Adverse events as posted: participants affected out of participants at risk, by group
GroupDeathsSerious eventsOther events
Adults With PTSD (18-55)Drug: oxytocin and placebo nasal spray (within-subjects design, blinded and counterbalanced for two lab sessions); dosage=24 international units (IU). Participant inserts nasal spray container 1cm into nostril at angle of 45 degrees and sprays. Will wait 15 seconds then repeat administration to other nostril (alternating between nostrils). Participants will receive 6 puffs in total (3 in each nostril). Oxytocin: See arm/group descriptions for dosage amount and procedure. Placebo: See arm/group descriptions for dosage amount and procedure.0 / 90 / 90 / 9
Trauma-exposed/No-PTSD Adults (18-55)Drug: oxytocin and placebo nasal spray (within-subjects design, blinded and counterbalanced for two lab sessions); dosage=24 international units (IU). Participant inserts nasal spray container 1cm into nostril at angle of 45 degrees and sprays. Will wait 15 seconds then repeat administration to other nostril (alternating between nostrils). Participants will receive 6 puffs in total (3 in each nostril). Oxytocin: See arm/group descriptions for dosage amount and procedure. Placebo: See arm/group descriptions for dosage amount and procedure.0 / 20 / 20 / 2

Each cell reads participants affected / participants at risk, as the registry posted them.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years up to 55 Years
Healthy volunteers
Accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Adults: age 18-55 * Be in good medical health * Be cooperative with testing * English is a language spoken in the family * PTSD as diagnosed by a certified clinician or the research team for PTSD group. Exclusion Criteria: * Moderate or severe acute or chronic medical illnesses (e.g.cardiac disease, diabetes, epilepsy, influenza). * History of hypertension with baseline blood pressure above 160 mm Hg (systolic) over 100 mm Hg (diastolic). * history of syncope and/or baseline blood pressure below 100 mm Hg (systolic). * weight \>300lb * The use of some psychotropic medications will not be allowed. Females taking contraceptive hormones will not be able to participate in the study. * Currently breast feeding or pregnant * For MRI ONLY: Any metal or electromagnetic implants * For MRI ONLY: Significant hearing loss or other severe sensory impairment * A fragile health status. * For MRI ONLY: A history of seizures or current use of anticonvulsants * Healthy adult controls (HC): * Be free of both neurological and psychiatric disorders (current and past) on the basis of self-report * Be free of psychiatric disorders

PepBank is a research reference. Talk to a doctor before you use any peptide.